Kathleen Drennan oversees Iris Global Clinical Trial Solutions by drawing on her 25 years of experience in pharmaceutical research and clinical trial development. She has implemented a system of integrated services and tools that offers significant opportunities in clinical trial acceleration and pre- and post-marketing, which has led to brand optimization.

Drennan spent the first 11 years of her career in cardiovascular research at the Upjohn-Pharmaceutical Company. Then as the founding President and Chief Operating Officer of the Chicago Center for Clinical Research (CCCR), Drennan developed for Rush-Presbyterian-St. Luke's Medical Center one of the largest and most successful independent research organizations in the country.

Drennan presides as Editor-in-Chief for Elsevier's prestigious journal, Controlled Clinical Trials. In addition, she has authored several articles regarding the impact of patient recruitment on clinical trials, which have published in PharmaVOICE, Pharmaceutical Executive, Drug Discovery Today, Women in Medicine and Applied Clinical Trials. Pharmaceutical Executive's April 2003 article featured her analysis of current industry challenges. Drennan also wrote A Guide to Patient Recruitment and Retention, which was published by CenterWatch in July of 2004.

In addition to her pharmaceutical industry experience, Drennan is a recognized pioneer in women's health research. During the past decade, she oversaw numerous high-profile national studies for women with heart disease, osteoporosis, obesity and estrogen replacement, including the HERS and PEPI trials. She is also one of the founding members of the Society for Women's Health Research in Washington, D.C., where she is also a member of the Board of Directors.

Drennan is an internationally known speaker and advisor on critical trial process-related issues, content and product development, and appropriate business and revenue models, including patient recruitment and clinical trial training.